Serum neurofilament light as a biomarker in progressive multiple sclerosis

There is an unmet need in multiple sclerosis (MS) therapy for treatments to stop progressive disability. The development of treatments may be accelerated if novel biomarkers are developed to overcome the limitations of traditional imaging outcomes revealed in early phase trials. In January 2019, the International Progressive MS Alliance convened a standing expert panel to consider potential tissue fluid biomarkers in MS in general and in progressive MS specifically. The panel focused their attention on neurofilament light chain (NfL) in serum or plasma, examining data from both relapsing and progressive MS. Here, we report the initial conclusions of the panel and its recommendations for further research. Serum NfL (sNfL) is a plausible marker of neurodegeneration that can be measured accurately, sensitively, and reproducibly, but standard procedures for sample processing and analysis should be established. Findings from relapsing and progressive cohorts concur and indicate that sNfL concentrations correlate with imaging and disability measures, predict the future course of the disease, and can predict response to treatment. Importantly, disease activity from active inflammation (i.e., new T2 and gadolinium-enhancing lesions) is a large contributor to sNfL, so teasing apart disease activity from the disease progression that drives insidious disability progression in progressive MS will be challenging. More data are required on the effects of age and comorbidities, as well as the relative contributions of inflammatory activity and other disease processes. The International Progressive MS Alliance is well positioned to advance these initiatives by connecting and supporting relevant stakeholders in progressive MS.

[1]  P. F. Kauff Group , 2000, Elegant Design.

[2]  R. Henry,et al.  Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. , 2019, JAMA neurology.

[3]  K. Blennow,et al.  Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. , 2019, JAMA neurology.

[4]  B. Bielekova,et al.  CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage , 2019, Multiple sclerosis.

[5]  M. Sormani,et al.  Blood neurofilament light as a potential endpoint in Phase 2 studies in MS , 2019, Annals of clinical and translational neurology.

[6]  L. Kappos,et al.  Blood neurofilament light chain as a biomarker of MS disease activity and treatment response , 2019, Neurology.

[7]  Nick C Fox,et al.  Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease , 2019, Nature Medicine.

[8]  K. Blennow,et al.  Commutability of the certified reference materials for the standardization of β-amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β-amyloid 1-40 measurements , 2018, Clinical chemistry and laboratory medicine.

[9]  Ankur Sharma Strategic platform selection and validation of biomarker assays to measure serum neurofilament light and heavy chain in multiple sclerosis , 2018 .

[10]  Ludwig Kappos,et al.  Neurofilaments as biomarkers in neurological disorders , 2018, Nature Reviews Neurology.

[11]  Sridar Narayanan,et al.  Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis , 2018, The New England journal of medicine.

[12]  K. Blennow,et al.  Evidence for sex difference in the CSF/plasma albumin ratio in ~20 000 patients and 335 healthy volunteers , 2018, Journal of cellular and molecular medicine.

[13]  P. Andersen,et al.  Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion , 2018, Annals of neurology.

[14]  K. Blennow,et al.  Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod , 2018, Multiple sclerosis.

[15]  Ludwig Kappos,et al.  Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis , 2018, Brain : a journal of neurology.

[16]  L. Kappos,et al.  Siponimod Reduces Neurofilament Light Chain Blood Levels in Secondary Progressive Multiple Sclerosis Patients (S8.006) , 2018, Neurology.

[17]  Sara Llufriu,et al.  Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome , 2018, Brain : a journal of neurology.

[18]  Ian A. Watson,et al.  Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis , 2017, Clinical and translational science.

[19]  K. Blennow,et al.  Monitoring disease activity in multiple sclerosis using serum neurofilament light protein , 2017, Neurology.

[20]  D. Menon,et al.  Serial Sampling of Serum Protein Biomarkers for Monitoring Human Traumatic Brain Injury Dynamics: A Systematic Review , 2017, Front. Neurol..

[21]  Ludwig Kappos,et al.  Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis , 2017, Annals of neurology.

[22]  Alzheimer's Disease Neuroimaging Initiative Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease , 2017 .

[23]  Vicente E. Torres,et al.  A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease , 2017, Kidney international reports.

[24]  Gavin Giovannoni,et al.  Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. , 2017, Multiple sclerosis and related disorders.

[25]  Henrik Zetterberg,et al.  Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa , 2016, Clinical chemistry and laboratory medicine.

[26]  J. Long,et al.  Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. , 2016, Contemporary clinical trials.

[27]  M. Staufenbiel,et al.  Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases , 2016, Neuron.

[28]  M. Staufenbiel,et al.  Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases , 2016, Neuron.

[29]  H. Siebner,et al.  Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis , 2016, Multiple sclerosis.

[30]  K. Blennow,et al.  Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study , 2015, EBioMedicine.

[31]  A. Thompson,et al.  Progressive MS: from pathophysiology to drug discovery , 2015, Multiple sclerosis.

[32]  D Polhamus,et al.  The future is now: Model‐based clinical trial design for Alzheimer's disease , 2015, Clinical pharmacology and therapeutics.

[33]  Richard Nicholas,et al.  Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial , 2014, The Lancet.

[34]  H. Siebner,et al.  Natalizumab in progressive MS , 2014, Neurology.

[35]  H. Zetterberg,et al.  Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis , 2014, Multiple sclerosis.

[36]  H. Larsson,et al.  Relationship between Cerebrospinal Fluid Biomarkers for Inflammation, Demyelination and Neurodegeneration in Acute Optic Neuritis , 2013, PloS one.

[37]  Ludwig Kappos,et al.  Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases , 2013, PloS one.

[38]  M. Sormani,et al.  MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials , 2013, The Lancet Neurology.

[39]  L. Kappos,et al.  A comparative study of CSF neurofilament light and heavy chain protein in MS , 2013, Multiple sclerosis.

[40]  O. Ciccarelli,et al.  Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS , 2012, Multiple sclerosis.

[41]  David H. Miller,et al.  Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial , 2010, The Lancet Neurology.

[42]  A. Thompson,et al.  Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis , 2009, Neurology.

[43]  L. Rosengren,et al.  Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS , 2003, Neurology.

[44]  N. Norgren,et al.  Monoclonal antibodies selective for low molecular weight neurofilaments. , 2002, Hybridoma and hybridomics.